All In Biotech

Drug Trial Radar · NCT06856577

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

A Multi-Center, Randomized, Double-Masked, Active-Comparator-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration (ARTEMIS)

Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 311 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

311

Actual

Start

Feb 28, 2025

Primary completion

Dec 22, 2026

Study completion Nov 23, 2030

Sponsor

Lead sponsor
Adverum Biotechnologies, Inc.Industry
Sponsor type
Industry
First posted
Mar 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection of Ixo-vec compared to an active comparator. The primary endpoint of this study is the mean change in best corrected visual acuity (BCVA) of Ixo-vec compared to an active comparator measured at an average of Weeks 52 and 56. Safety, tolerability, and efficacy will be evaluated throughout the study.

Conditions

  • Neovascular Age-Related Macular Degeneration (nAMD)
  • Wet AMD

Interventions

  • Ixo-vecGenetic

    Ixo-vec will be administered intravitreally.

  • AfliberceptDrug

    Aflibercept will be administered intravitreally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from Baseline in Best-Corrected Visual Acuity (BCVA) based on an average at Weeks 52 and 56Time frame: Baseline, Week 52 and Week 56

Locations

75 sites in 1 country. Site status is shown where the registry gives one.

  • Adverum Clinical Site 223

    Gilbert, Arizona

  • Adverum Clinical Site 178

    Phoenix, Arizona

  • Adverum Clinical Site 126

    Phoenix, Arizona

  • Adverum Clinical Site 229

    Scottsdale, Arizona

  • Adverum Clinical Site 159

    Tucson, Arizona

  • Adverum Clinical Site 198

    Springdale, Arkansas

  • Adverum Clinical Site 109

    Bakersfield, California

  • Adverum Clinical Site 100

    Beverly Hills, California

  • Adverum Clinical Site 201

    Campbell, California

  • Adverum Clinical Site 172

    Encino, California

  • Adverum Clinical Site 169

    Fullerton, California

  • Adverum Clinical Site 224

    Huntington Beach, California

  • Adverum Clinical Site 215

    Redlands, California

  • Adverum Clinical Site 164

    Riverside, California

  • Adverum Clinical Site 140

    Sacramento, California

  • Adverum Clinical Site 212

    Sacramento, California

  • Adverum Clinical Site 175

    Santa Barbara, California

  • Adverum Clinical Site 202

    Torrance, California

  • Adverum Clinical Site 189

    Walnut Creek, California

  • Adverum Clinical Site 200

    Denver, Colorado

  • Adverum Clinical Site 116

    Lakewood, Colorado

  • Adverum Clinical Site 165

    Waterford, Connecticut

  • Adverum Clinical Site 184

    Deerfield Beach, Florida

  • Adverum Clinical Site 176

    Fort Lauderdale, Florida

  • Adverum Clinical Site 221

    Fort Myers, Florida

  • Adverum Clinical Site 168

    Jacksonville, Florida

  • Adverum Clinical Site 214

    Lakeland, Florida

  • Adverum Clinical Site 213

    Orlando, Florida

  • Adverum Clinical Site 230

    Pensacola, Florida

  • Adverum Clinical Site 124

    Pompano Beach, Florida

  • Adverum Clinical Site 183

    South Miami, Florida

  • Adverum Clinical Site 120

    St. Petersburg, Florida

  • Adverum Clinical Site 193

    Tampa, Florida

  • Adverum Clinical Site 182

    Augusta, Georgia

  • Adverum Clinical Site 179

    Oak Forest, Illinois

  • Adverum Clinical Site 207

    Oak Park, Illinois

  • Adverum Clinical Site 195

    Carmel, Indiana

  • Adverum Clinical Site 205

    Carmel, Indiana

  • Adverum Clinical Site 197

    Hagerstown, Maryland

  • Adverum Clinical Site 204

    Hagerstown, Maryland

Showing 40 of 75 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.